Trials / Sponsors / Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc.
Industry · 3 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degenerat Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration | Phase 2 | 2020-12-29 |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration | Phase 2 | 2020-07-30 |
| Completed | First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration | Phase 1 | 2019-12-19 |